rabies vaccine adsorbed
Trade name: BioRab
Approved
Mar 18, 1988
The rabies vaccine is a vaccine used to prevent rabies. There are several rabies vaccines available that are both safe and effective. Vaccinations must be administered prior to rabies virus exposure or within the latent period after exposure to prevent the disease. Transmission of rabies virus to humans typically occurs through a bite or scratch from an infectious animal, but exposure can occur through indirect contact with the saliva from an infectious individual. — Wikipedia
Clinical trial activity
5 trials · 10 clinical orgs · 1 marketing orgs
Earliest trial started Aug 29, 2018 (NCT03656198)
Timeline
1980s
- Mar 18, 1988
Earliest FDA Approval
1990s
- Nov 12, 1998
Emergent BioSolutions — First NDA Organization
- Nov 12, 1998
Emergent BioSolutions — NDA Secondary Org
- Nov 12, 1998
Emergent BioSolutions — NDA Organization
2020s
- Jan 1, 2025
Earliest Phase 2 Sponsor(trial)
Indications
Approved for
Mechanism of action
- Lyssavirus rabiesImmunity, active
Lyssavirus rabies immunity, active
Approval history
- approvedMar 18, 1988
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaRabies vaccine ↗
Also known as
- biorab
- rabies vaccine adsorbed
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07183371 | Phase 2 | Nov 30, 2025 | European and Developing Countries Clinical Trials Partnership (EDCTP), European Vaccine Initiative (EVI), Heidelberg, Germany, Government of Germany, Institut et Haute école de la Santé, La Source, University of Oxford |
| NCT07147400 | Phase 2 | Aug 22, 2025 | National Institute of Allergy and Infectious Diseases (NIAID), Serum Institute of India Pvt. Ltd. |
| NCT05937113 | Phase 4 | Jun 13, 2020 | Vabiotech, Vietnam Military Medical University |
| NCT03741270 | Phase 4 | Oct 24, 2018 | Ross University School of Veterinary Medicine, Serum Institute of India Pvt. Ltd. |
| NCT03656198 | Phase 4 | Aug 29, 2018 | Ross University School of Veterinary Medicine, Serum Institute of India Pvt. Ltd. |
Organizations
Research & Development (10)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Serum Institute of India Pvt. Ltd. | For profit | 3 | 1 | 2 | 2018 |
| Ross University School of Veterinary Medicine | Academic/Hospital | 2 | 2 | 1 | 2018 |
| European and Developing Countries Clinical Trials Partnership (EDCTP) | Academic/Hospital | 1 | 0 | 1 | 2025 |
| European Vaccine Initiative (EVI), Heidelberg, Germany | Government | 1 | 0 | 1 | 2025 |
| Government of Germany | Government | 1 | 0 | 1 | 2025 |
| Institut et Haute école de la Santé, La Source | Academic/Hospital | 1 | 0 | 1 | 2025 |
| National Institute of Allergy and Infectious Diseases (NIAID) | Government | 1 | 0 | 1 | 2025 |
| University of Oxford | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Vabiotech | Government | 1 | 0 | 1 | 2020 |
| Vietnam Military Medical University | Government | 1 | 1 | 1 | 2020 |
Marketing (2)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| Emergent BioSolutions | For profit | NDA2 | Nov 12, 1998 |
| Emergent BioSolutions | For profit | NDA | Nov 12, 1998 |